Understanding Cravings

What is Naltrexone and How Does It Work?

by Reframe Research Team • 3 min read

If you're exploring ways to change your relationship with alcohol, you're not alone, and you have more options than you might realize. One of the most effective tools available is naltrexone, an FDA-approved medication that's been helping people change their relationship with alcohol for over 30 years.

Here's what makes naltrexone different: it doesn't make you sick when you drink like some other medications, and it doesn't require you to quit cold turkey. Instead, it works with your brain's natural chemistry to gradually reduce the appeal of alcohol. Think of it as a reset button for the reward pathways that make drinking feel so compelling.

Originally developed in the 1960s and approved for alcohol use disorder in 1994, naltrexone has a long track record of safety and effectiveness. Let's explore how it works and whether it might be a fit for your goals.

What is Naltrexone?

Naltrexone is a medication that is classified as an opioid antagonist, which means it blocks opioid receptors in your brain: specifically, the mu-opioid receptors that play a key role in reward and pleasure. These receptors are part of your brain's natural reward system that responds to many experiences, including drinking alcohol.

Naltrexone comes in two forms:

Most people using naltrexone for alcohol reduction choose the oral tablet because of its ease and adaptability to different dosing strategies.

How Naltrexone Interrupts the Brain's Reward Pathway

When you drink alcohol, your brain releases endorphins, or natural neurochemicals that create feelings of pleasure and reward. These endorphins bind to opioid receptors, producing the "buzz" or euphoria associated with drinking. This reward response is what reinforces drinking behavior. Your brain learns to associate alcohol with the reward response, which strengthens cravings and the desire to drink more.

Naltrexone blocks opioid receptors before endorphins can bind to them. When you drink alcohol while taking naltrexone, your brain still releases endorphins, but they can't attach to the blocked receptors. This means the "buzz" from drinking is diminished or absent.

Without that rewarding feeling, your brain's association between alcohol and pleasure begins to weaken. Over time, drinking becomes less appealing. This shift occurs not because you're forcing yourself to abstain, but because your brain is genuinely losing interest.

What This Looks Like in Real Life

Clinical studies show that naltrexone reduces both the frequency of drinking days and the amount consumed per occasion, particularly when combined with therapy or support. Research also indicates that naltrexone is more effective at reducing cravings between drinking episodes than other alcohol reduction medications.

Here's what many people experience:

Naltrexone doesn't eliminate alcohol's effects entirely: you can still become intoxicated if you drink enough. Your judgment, coordination, and reaction time are still impaired, and you should never drive or operate machinery after drinking. What changes is the subjective enjoyment and the compelling urge to keep drinking once you start. 

National Center for Biotechnology Information. (n.d.). MeSH descriptor data [Naltrexone]. NCBI Bookshelf. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK64042/

Younger, J., & Mackey, S. (2021). Long-term low-dose naltrexone in chronic pain syndromes: An open-label study. Pain Medicine, 22(6), 1334–1339. https://pmc.ncbi.nlm.nih.gov/articles/PMC8120985/

Mayo Clinic. (2025). Naltrexone (Oral Route): Description. Retrieved from https://www.mayoclinic.org/drugs-supplements/naltrexone-oral-route/description/drg-20068408

U.S. Food and Drug Administration. (2013, October). REVIA (naltrexone hydrochloride) tablets, for oral use [Drug label]. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf

O'Brien, C. P. (2008). Naltrexone for the management of alcohol dependence. The New England Journal of Medicine, 359(16), 1709–1714. https://pmc.ncbi.nlm.nih.gov/articles/PMC2565602/